世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い



肝炎テストソリューション・診断市場:疾病タイプ毎(B型肝炎、HCV、HAV、HDV)、技術毎(ELISA、RDT、PCR、転写増幅)、エンドユーザ毎(病院、診断研究所、血液銀行、養護施設) - 2023年までの世界市場予測

Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis B, HCV, HAV, HDV), Technology (ELISA, RDT, PCR, Transcription Mediated Amplification), End User (Hospitals, Diagnostic Laboratories, Blood Banks, Nursing Homes) - Global Forecast to 2023

 

出版社 出版日電子媒体価格ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2018年10月 US$ 4,950
シングルユーザライセンス
113p98点

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)の肝炎テストソリューション・診断市場に関する調査レポートです。

“The hepatitis test solution/diagnosis market is projected to register a CAGR of 4.9%.”

The hepatitis test solution/diagnosis market is expected to reach USD 3.37 billion by 2023 from USD 2.66 billion in 2018, growing at a CAGR of 4.9% during the forecast period. The growth of this market can be attributed to the high burden of hepatitis worldwide, benefits offered by point of care instruments & kits, and initiatives taken by government and non-government organizations. However, lack of mandate for NAT in developing countries and the high cost of NAT test are expected to restrain the growth of this market during the forecast period.

“The rapid diagnostics test segment of the hepatitis test solution/diagnosis market, by technology, is projected to grow at the highest CAGR in 2018.”

By technology, the hepatitis test solution/diagnosis market is segmented into ELISA, rapid diagnostics test, PCR, INAAT, and other technologies. RDT is projected to grow at the highest CAGR during the forecast period. This growth is mainly attributed to the low cost of this test type, its high analytical sensitivity, and its ability to detect all known 11 subtypes of HBsAg.

“The hepatitis B segment is expected to account for the largest share of the market, by disease type, in 2018.”

The market is classified on the basis of disease type into hepatitis B, hepatitis C, and other hepatitis disease. In terms of value, the hepatitis B segment is expected to account for the largest share of the market in 2018. This can primarily be attributed to the rising prevalence of hepatitis B, availability of a large number of hepatitis B diagnostic tests, and the increasing adoption of NAT test in HBV blood screening.

“North America to dominate the market in 2018.”

North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market in 2018. This is primarily attributed to factors such as rising adoption of advanced technologies, developed healthcare systems in the US and Canada, and the presence of a large number of leading national clinical laboratories. Followed by North America, Europe is expected to account for the second-largest share of the global hepatitis test solution/diagnosis market in 2018.

Break-up profile of primaries:

- By Company Type- Tier 1-32%, Tier 2-42% and Tier 3-26%
- By Designation-C-level-23%, D-level-35% and Others-42%
- By Region-North America-39%, Europe-25%, Asia Pacific-26%, and RoW-10%

Abbott Laboratories (US), Roche (Switzerland), Bio-Rad (US), Siemens (Germany), DiaSorin (Italy), QIAGEN (Netherlands), Danaher (US), bioM-rieux (France), and Grifols (Spain) are some of the key players operating in this market.

Research Coverage:

The hepatitis test solution/diagnosis market studied in this report is segmented by disease type, technology, end user, and region. The study tracks and analyzes competitive developments such as product launches; expansions; agreements, partnerships, and collaborations; and acquisitions. It also profiles the key players and their core competencies within the hepatitis test solution/diagnosis market.

Reasons to buy this report:

The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on portfolios offered by the top players in the global hepatitis test solution/diagnosis market. The report analyzes the hepatitis test solution/diagnosis market by disease type, technology, end user, and region.

- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the hepatitis test solution/diagnosis market

- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for hepatitis test solution/diagnosis products across regions.

- Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the global hepatitis test solution/diagnosis market

- Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global hepatitis test solution/diagnosis market



目次

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 MARKET SCOPE 14
1.3.1 YEARS COVERED FOR THE STUDY 14
1.4 CURRENCY 15
1.5 LIMITATIONS 15
1.6 STAKEHOLDERS 15

2 RESEARCH METHODOLOGY 16
2.1 PRIMARY DATA 17
2.1.1 KEY DATA FROM PRIMARY SOURCES 17
2.1.2 KEY INDUSTRY INSIGHTS 18
2.2 SECONDARY DATA 19
2.3 KEY DATA FROM SECONDARY SOURCES 19
2.4 MARKET SIZE ESTIMATION 20
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 22
2.5.1 ASSUMPTIONS FOR THE STUDY 23

3 EXECUTIVE SUMMARY 24

4 PREMIUM INSIGHTS 27
4.1 HEPATITIS TESTING: MARKET OVERVIEW 27
4.2 GEOGRAPHIC ANALYSIS: HEPATITIS TESTING MARKET, BY DISEASE TYPE (2018) 28
4.3 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018 VS. 2023 28
4.4 HEPATITIS TESTING MARKET, BY END USER, 2016-2023 29

5 MARKET OVERVIEW 30
5.1 INTRODUCTION 30
5.1.1 DRIVERS 31
5.1.1.1 High burden of hepatitis 31
5.1.1.2 Increasing blood transfusion and donations 31
5.1.1.3 Benefits of PoC instruments & kits 32
5.1.1.4 Awareness initiatives 33
5.1.2 RESTRAINTS 33
5.1.2.1 High Cost of NAT 33
5.1.2.2 Lack of mandate for NAT in developing countries 33
5.1.3 OPPORTUNITIES 34
5.1.3.1 Emerging markets 34

6 HEPATITIS TESTING MARKET, BY DISEASE TYPE 35
6.1 INTRODUCTION 36
6.2 HEPATITIS B (HBV) 36
6.3 HEPATITIS C (HCV) 37
6.4 OTHER HEPATITIS DISEASES 39

7 HEPATITIS TESTING MARKET, BY TECHNOLOGY 41
7.1 INTRODUCTION 42
7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 42
7.3 RAPID DIAGNOSTIC TESTS (RDT) 44
7.4 POLYMERASE CHAIN REACTION (PCR) 45
7.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) 47
7.6 OTHER TECHNOLOGIES 48

8 HEPATITIS TESTING MARKET, BY END USER 50
8.1 INTRODUCTION 51
8.2 HOSPITAL & DIAGNOSTIC LABORATORIES 51
8.3 BLOOD BANKS 53
8.4 OTHER END USERS 54

9 HEPATITIS TESTING MARKET, BY REGION 56
9.1 INTRODUCTION 57
9.2 NORTH AMERICA 58
9.2.1 US 61
9.2.2 CANADA 64
9.3 EUROPE 66
9.3.1 GERMANY 67
9.3.2 UK 68
9.3.3 REST OF EUROPE 70
9.4 ASIA PACIFIC 71
9.5 REST OF THE WORLD 74

10 COMPETITIVE LANDSCAPE 76
10.1 MARKET OVERVIEW 76
10.2 MARKET RANKING ANALYSIS, 2017 76
10.3 COMPETITIVE SITUATION AND TRENDS 77
10.3.1 COLLABORATIONS, AGREEMENTS, AND PARTNERSHIPS 77
10.3.2 PRODUCT LAUNCHES AND APPROVALS 78
10.3.3 ACQUISITIONS 78
-
11 COMPANY PROFILES 80
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
11.1 ABBOTT LABORATORIES, INC. 80
11.2 ROCHE DIAGNOSTICS 83
11.3 BIO-RAD LABORATORIES 86
11.4 SIEMENS HEALTHINEERS 88
11.5 DIASORIN 91
11.6 QIAGEN 94
11.7 DANAHER CORPORATION 95
11.8 GRIFOLS 97
11.9 BIOM-RIEUX SA 100
11.10 ORTHO CLINICAL DIAGNOSTICS (A PART OF THE CARLYLE GROUP) 102
11.11 FUJIREBIO, INC. (A PART OF MIRACA GROUP) 104
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

12 APPENDIX 105
12.1 INSIGHTS OF INDUSTRY EXPERTS 105
12.2 DISCUSSION GUIDE 106
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 109
12.4 AVAILABLE CUSTOMIZATIONS 111
12.5 RELATED REPORTS 111
12.6 AUTHOR DETAILS 112

 

LIST OF TABLES

TABLE 1 GLOBAL HEPATITIS PREVALENCE (MILLION PEOPLE APPROX.), 2015 31
TABLE 2 INCREASE IN VOLUNTARY NON-REMUNERATED BLOOD DONATIONS AND TOTAL BLOOD DONATIONS, 2008-2013 32
TABLE 3 HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2016-2023 (USD MILLION) 36
TABLE 4 HEPATITIS B TESTING MARKET, BY REGION, 2016-2023 (USD MILLION) 37
TABLE 5 NORTH AMERICA: HEPATITIS B TESTING MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 37
TABLE 6 HEPATITIS C TESTING MARKET, BY REGION, 2016-2023 (USD MILLION) 38
TABLE 7 NORTH AMERICA: HEPATITIS C TESTING MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 38
TABLE 8 HEPATITIS TESTING MARKET FOR OTHER DISEASES, BY REGION,
2016-2023 (USD MILLION) 39
TABLE 9 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER DISEASES,
BY COUNTRY, 2016-2023 (USD MILLION) 40
TABLE 10 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION) 42
TABLE 11 HEPATITIS TESTING MARKET FOR ELISA, BY REGION, 2016-2023 (USD MILLION) 43
TABLE 12 NORTH AMERICA: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY,
2016-2023 (USD MILLION) 43
TABLE 13 EUROPE: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY,
2016-2023 (USD MILLION) 43
TABLE 14 HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY REGION,
2016-2023 (USD MILLION) 44
TABLE 15 NORTH AMERICA: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS,
BY COUNTRY, 2016-2023 (USD MILLION) 45
TABLE 16 EUROPE: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS,
BY COUNTRY, 2016-2023 (USD MILLION) 45
TABLE 17 HEPATITIS TESTING MARKET FOR PCR, BY REGION, 2016-2023 (USD MILLION) 46
TABLE 18 NORTH AMERICA: HEPATITIS TESTING MARKET FOR PCR, BY COUNTRY,
2016-2023 (USD MILLION) 46
TABLE 19 EUROPE: HEPATITIS TESTING MARKET FOR PCR, BY COUNTRY,
2016-2023 (USD MILLION) 46
TABLE 20 HEPATITIS TESTING MARKET FOR INAAT, BY REGION, 2016-2023 (USD MILLION) 47
TABLE 21 NORTH AMERICA: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY,
2016-2023 (USD MILLION) 47
TABLE 22 EUROPE: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY,
2016-2023 (USD MILLION) 48
TABLE 23 HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2016-2023 (USD MILLION) 48
TABLE 24 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2016-2023 (USD MILLION) 49
TABLE 25 EUROPE: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2016-2023 (USD MILLION) 49
TABLE 26 HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION) 51
TABLE 27 HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABS, BY REGION, 2016-2023 (USD MILLION) 52
TABLE 28 NORTH AMERICA: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABS, BY COUNTRY, 2016-2023 (USD MILLION) 52
TABLE 29 EUROPE: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABS,
BY COUNTRY, 2016-2023 (USD MILLION) 52
TABLE 30 HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY REGION,
2016-2023 (USD MILLION) 53
TABLE 31 NORTH AMERICA: HEPATITIS TESTING MARKET FOR BLOOD BANKS,
BY COUNTRY, 2016-2023 (USD MILLION) 53
TABLE 32 EUROPE: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY,
2016-2023 (USD MILLION) 54
TABLE 33 HEPATITIS TESTING MARKET FOR OTHER END USERS, BY REGION,
2016-2023 (USD MILLION) 54
TABLE 34 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER END USERS,
BY COUNTRY, 2016-2023 (USD MILLION) 55
TABLE 35 EUROPE: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2016-2023 (USD MILLION) 55
TABLE 36 HEPATITIS TESTING MARKET, BY REGION, 2016-2023 (USD MILLION) 58
TABLE 37 NORTH AMERICA: HEPATITIS TESTING MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 60
TABLE 38 NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2016-2023 (USD MILLION) 60
TABLE 39 NORTH AMERICA: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2016-2023 (USD MILLION) 60
TABLE 40 NORTH AMERICA: HEPATITIS TESTING MARKET, BY END USER,
2016-2023 (USD MILLION) 61
TABLE 41 HAV AND HBV VACCINATION COVERAGE: US (2014-2016) 62
TABLE 42 US: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2016-2023 (USD MILLION) 62
TABLE 43 US: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION) 63
TABLE 44 US: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION) 63
TABLE 45 CANADA: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2016-2023 (USD MILLION) 64
TABLE 46 CANADA: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2016-2023 (USD MILLION) 65
TABLE 47 CANADA: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION) 65
TABLE 48 EUROPE: HEPATITIS TESTING MARKET, BY COUNTRY, 2016-2023 (USD MILLION) 66
TABLE 49 EUROPE: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2016-2023 (USD MILLION) 66
TABLE 50 EUROPE: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2016-2023 (USD MILLION) 67
TABLE 51 EUROPE: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION) 67
TABLE 52 GERMANY: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2016-2023 (USD MILLION) 68
TABLE 53 GERMANY: HEPATITIS TESTING MARKET, BY END USER,
2016-2023 (USD MILLION) 68
TABLE 54 UK: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION) 69
TABLE 55 UK: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION) 69
TABLE 56 ROE: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION) 70
TABLE 57 ROE: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION) 70
TABLE 58 ESTIMATED PREVALENCE OF CHRONIC HBV AND HCV: ASIA PACIFIC 71
TABLE 59 ASIA-PACIFIC: COST COVERAGE FOR DIAGNOSIS OF CHRONIC VIRAL HEPATITIS 71
TABLE 60 APAC: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2016-2023 (USD MILLION) 73
TABLE 61 APAC: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION) 73
TABLE 62 APAC: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION) 73
TABLE 63 ROW: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2016-2023 (USD MILLION) 74
TABLE 64 ROW: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION) 74
TABLE 65 ROW: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION) 75
TABLE 66 RANK OF COMPANIES IN THE HEPATITIS TESTING MARKET, 2017 76
TABLE 67 COLLABORATIONS, AGREEMENTS, AND PARTNERSHIPS 77
TABLE 68 PRODUCT LAUNCHES AND APPROVALS, 2015-2018 78
TABLE 69 ACQUISITIONS, 2015-2018 78

 

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 16
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 18
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 21
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 21
FIGURE 5 DATA TRIANGULATION 22
FIGURE 6 HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018 VS. 2023 24
FIGURE 7 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018 VS. 2023 25
FIGURE 8 HEPATITIS TESTING MARKET, BY END USER, 2018 VS. 2023 25
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE HEPATITIS TESTING MARKET 26
FIGURE 10 HIGH BURDEN OF HEPATITIS & INITIATIVES TAKEN BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS-KEY FACTORS DRIVING MARKET GROWTH 27
FIGURE 11 HEPATITIS B SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2018 28
FIGURE 12 ELISA WILL CONTINUE TO DOMINATE THE HEPATITIS TESTING MARKET,
BY TECHNOLOGY, IN 2023 28
FIGURE 13 HOSPITAL & DIAGNOSTIC LABORATORIES TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2018 29
FIGURE 14 HEPATITIS TESTING MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 30
FIGURE 15 HEPATITIS TESTING MARKET: GEOGRAPHIC SNAPSHOT (2018) 57
FIGURE 16 NORTH AMERICA: MARKET SNAPSHOT 59
FIGURE 17 REPORTED ACUTE (NEW) CASES OF HEPATITIS C: US (2010-2016) 62
FIGURE 18 ASIA PACIFIC: HEPATITIS TESTING MARKET SNAPSHOT 72
FIGURE 19 KEY DEVELOPMENTS IN THE HEPATITIS TESTING MARKET BETWEEN
2015 AND 2017 76
FIGURE 20 ABBOTT: COMPANY SNAPSHOT (2017) 80
FIGURE 21 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2017) 83
FIGURE 22 BIO-RAD: COMPANY SNAPSHOT (2017) 86
FIGURE 23 SIEMENS AG: COMPANY SNAPSHOT (2017) 88
FIGURE 24 DIASORIN: COMPANY SNAPSHOT (2017) 91
FIGURE 25 QIAGEN: COMPANY SNAPSHOT (2017) 94
FIGURE 26 DANAHER: COMPANY SNAPSHOT (2017) 95
FIGURE 27 GRIFOLS: COMPANY SNAPSHOT (2017) 97
FIGURE 28 BIOM-RIEUX: COMPANY SNAPSHOT (2017) 100
FIGURE 29 MIRACA: COMPANY SNAPSHOT (2017) 104

 

COPYRIGHT(C) 2011-2019 DATA RESOURCES, Inc. ALL RIGHTS RESERVED.